Make Sure Moleculin Biotech, Inc. (Nasdaq: MBRX) is on Your Watchlist Early This Morning!

Moleculin Biotech, Inc. (Nasdaq: MBRX) Comes Backed by Several Potential Catalysts Including:

Analyst Coverage: Jonathan Aschoff ($40 target, +1,546% upside potential ) and Jason McCarthy ($20 target, +723% upside potential ) point to significant growth potential.

Razor Thin Float: Less than 2.8M shares in public float could lead to the potential for big swings and volatility..

Under the Radar: With a market cap under $7M, Moleculin Biotech, Inc. (Nasdaq: MBRX) remains largely unnoticed by the broader market.

FDA Milestones: Moleculin Biotech, Inc. (Nasdaq: MBRX) has secured

multiple FDA clearances for its therapies, including WP1066.

Pull Up (Nasdaq: MBRX) and Start Your Research, There’s Less

Than 2.8M Shares Available to the Public!

September 23, 2024

Dear Reader,

Moleculin Biotech, Inc. (Nasdaq: MBRX) just revealed promising in vivo efficacy data for its next-generation anthracycline, Annamycin, in orthotopic and experimental lung metastatic models of sarcoma.

Presented at the prestigious IASLC 2024 World Conference on Lung Cancer, the data showed statistically significant inhibition of tumor growth and improved survival outcomes—all without cardiotoxicity.

This exciting development could signal a new era for lung cancer treatment.

See Full Article Here.

In fact, recent analyst coverage has our office buzzing about Moleculin Biotech, Inc. (Nasdaq: MBRX).

And with a market cap currently under $7M, as of September 20th, Moleculin Biotech, Inc. (Nasdaq: MBRX) appears to be flying under Wall Street’s radar, until now.

Keep reading to see why Moleculin Biotech, Inc. (Nasdaq: MBRX) needs to be on your watchlist tomorrow morning.

Moleculin Biotech, Inc. (Nasdaq: MBRX) is a Phase 3 clinical-stage pharmaceutical company dedicated to advancing an innovative pipeline of therapeutic candidates designed to tackle some of the most challenging tumors and viruses.

The company’s focus on addressing critical areas of unmet medical need is gaining attention, particularly through its development of next-generation dru-gs targeting aggressive cancers like relapsed or refractory acute myeloid leukemia (AML), soft tissue sarcoma (STS) lung metastases, and brain tumors.

Lead Program: Annamycin

Annamycin is being developed to treat relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases—both notoriously difficult to treat.

The innovation behind Annamycin lies in its potential to address critical safety concerns and increase efficacy where traditional therapies fall short.

The company’s ongoing development of Annamycin is reaching a critical phase with the initiation of the MIRACLE (Moleculin R/R AML AnnAraC Clinical Evaluation) Trial (MB-108).

This Phase 3, adaptive design trial will evaluate Annamycin in combination with cytarabine, referred to as AnnAraC, for the treatment of relapsed or refractory AML.

The MIRACLE trial follows the success of a Phase 1B/2 study (MB-106), which demonstrated promising results, de-risking the development pathway toward potential approval.

With input from the FDA, Moleculin Biotech, Inc. (Nasdaq: MBRX) is confident in the future of Annamycin, though further filings and feedback from regulatory bodies remain part of the journey.

Expanding the Pipeline: WP1066 and Immuno-Oncology

Beyond Annamycin, Moleculin Biotech, Inc. (Nasdaq: MBRX)’scommitment to innovative cancer treatments is reflected in its development of WP1066, an immune/transcription modulator capable of inhibiting oncogenic transcription factors such as p-STAT3.

WP1066 has shown the ability to stimulate the body’s natural immune response, making it a powerful candidate for targeting brain tumors, pancreatic cancer, and other difficult-to-treat malignancies.

In a recent groundbreaking development, Moleculin Biotech, Inc. (Nasdaq: MBRX) announced the treatment of the first patients in a Phase 2 clinical trial evaluating WP1066 in combination with radiation therapy for the treatment of glioblastoma (NU 21C06).

This investigator-initiated study, conducted at Northwestern University and funded by the National Institutes of Health (NIH) and BrainUp®, represents a significant step forward in the company’s efforts to develop new, effective therapies for this aggressive form of brain cancer.

WP1066 in Combination with Radiation Therapy: A New Hope for Glioblastoma

Despite advancements in cancer treatment, the prognosis for glioblastoma patients remains grim, with a median survival rate of only 15 months.

As the most common and aggressive malignant primary brain tumor, glioblastoma has defied significant advancements in survival rates over the past three decades.

Moleculin Biotech, Inc. (Nasdaq: MBRX)’s Phase 2 study aims to address this urgent need by combining WP1066 with radiation therapy. Preclinical models have already demonstrated the combination’s potential for eliciting both a strong therapeutic response and immune memory in glioblastoma.

The study’s primary outcome measure will focus on progression-free survival, with secondary measures including tumor microenvironment analysis, making this trial a critical milestone in the search for more effective treatments for brain cancer.

The importance of this trial is further underscored by the support it has garnered from the NIH and BrainUp®, a non-pro-fit organization committed to raising awareness and support for brain cancer research.

By advancing WP1066 in collaboration with Northwestern University, Moleculin Biotech, Inc. (Nasdaq: MBRX) is not only pursuing cutting-edge cancer therapies but also forging partnerships that enhance the potential for positive outcomes in patients.

Beyond Oncology: WP1122 for Viral Infections

In addition to its oncology pipeline, Moleculin is expanding its reach into virology with WP1122, an antimetabolite being developed for the potential treatment of viruses, including the one that caused the recent pandemic, and certain cancer indications.

WP1122 has garnered attention for its ability to disrupt viral metabolism, offering a potential new treatment modality for viral infections that have otherwise limited therapeutic options.

Moleculin’s forward-thinking approach to dr-ug development positions it as a key player in both the oncology and antiviral landscapes.

With a portfolio that addresses hard-to-treat diseases and an eye on advancing clinical trials, the company is uniquely poised to make a significant impact on global health.

Recent Developments: Accelerating Innovation in Cancer Treatment

Moleculin’s recent developments in treating glioblastoma and AML reflect its commitment to transforming the landscape of cancer treatment.

The Phase 2 clinical trial for WP1066 in combination with radiation therapy marks a significant leap forward in glioblastoma research, and the upcoming MIRACLE Phase 3 trial for Annamycin in AML has the potential to address one of the most challenging blood cancers.

Both efforts are backed by rigorous clinical research and collaborative partnerships with leading institutions like Northwestern University, bolstered by funding from major organizations like the NIH.

Moleculin Biotech, Inc. (Nasdaq: MBRX)’s Potential to Revolutionize Cancer Therapy

With its focus on addressing the most challenging tumors and viruses, Moleculin Biotech, Inc. stands at the forefront of innovative pharmaceutical development.

The company’s ability to advance its pipeline of next-generation therapies, particularly Annamycin and WP1066, reflects its dedication to improving patient outcomes in areas where traditional therapies have often failed.

The significance of its recent developments, especially the initiation of the Phase 2 glioblastoma trial and the MIRACLE Phase 3 trial for AML, cannot be overstated.

These efforts highlight Moleculin Biotech, Inc. (Nasdaq: MBRX)’spotential to deliver life-saving treatments and transform the standard of care for patients facing some of the most aggressive diseases.

With strong backing from academic institutions, the NIH, and patient advocacy groups, Moleculin Biotech, Inc. (Nasdaq: MBRX)’s mission to provide innovative therapeutic options for hard-to-treat cancers is well on its way to making a lasting impact.

7 reasons why Moleculin Biotech, Inc. (Nasdaq: MBRX) needs to be on your watchlist this morning.

1. Analyst Coverage: With Jonathan Aschoff, Ph.D., from ROTH reiterating a $40 target and Jason McCarthy, Ph.D., from Maxim Group assigning a $20 target, Moleculin Biotech, Inc. (Nasdaq: MBRX) presents a significant potential upside, especially considering the company is currently around $2.43.

2. Razor Thin Float: With fewer than 2.8M shares available in its public float, Moleculin Biotech, Inc. (Nasdaq: MBRX) could have the potential for big swings and increased volatility if demand shifts, making it one company to keep an eye on.

3. Under the Radar: With a market cap under $7M as of September 20th, Moleculin Biotech, Inc. (Nasdaq: MBRX) appears to be flying under the radar, making it a company to consider researching before broader market attention possibly increases.

4. Recent Phase 2 Trial in Glioblastoma: Patients have recently begun treatment in a Phase 2 trial combining WP1066 with radiation therapy for glioblastoma. Conducted by Northwestern University, this trial, which is supported by the NIH and BrainUp®, represents a significant advancement. Moleculin Biotech, Inc. (Nasdaq: MBRX) is making strides toward new therapeutic options for this aggressive brain cancer.

5. Cutting-Edge Cancer Therapeutics: Annamycin is a next-generation therapeutic being developed for relapsed or refractory AML and soft tissue sarcoma lung metastases. Designed to overcome multidr-ug resistance and avoid the cardiotoxicity of traditional therapies, it’s part of the innovative pipeline at Moleculin Biotech, Inc. (Nasdaq: MBRX).

6. Phase 3 Clinical Trials: The MIRACLE trial, a pivotal Phase 3 study of Annamycin in combination with cytarabine, is aimed at tackling relapsed or refractory AML. Moleculin Biotech, Inc. (Nasdaq: MBRX) is advancing this therapeutic candidate based on positive earlier-phase results and regulatory guidance.

7. FDA Regulatory Milestones: Regulatory progress has been a key factor in advancing clinical programs at Moleculin Biotech, Inc. (Nasdaq: MBRX).The U.S. FDA has provided clearance for several Investigational New Dr-ug applications, including WP1066, which is advancing through clinical phases under the FDA’s guidance.

At this critical stage, Moleculin Biotech, Inc. (Nasdaq: MBRX) is making significant strides with strong analyst coverage, groundbreaking cancer therapeutics, and innovative clinical trials. With a market cap under $7M and fewer than 2.8M shares in its public float, the potential for big movements and volatility is evident.

The company’s lead therapies, such as Annamycin and WP1066, are progressing through pivotal Phase 3 and Phase 2 trials, targeting some of the most challenging cancers. Supported by collaborations with leading institutions like Northwestern University and funding from organizations such as NIH and BrainUp®, Moleculin Biotech, Inc. (Nasdaq: MBRX) is advancing its clinical programs with FDA guidance.

With a growing pipeline that now also includes treatments for viral infections, Moleculin Biotech, Inc. (Nasdaq: MBRX) is expanding its influence in both oncology and virology, positioning itself as one company to keep an eye on.

Make sure Moleculin Biotech, Inc. (Nasdaq: MBRX) is at the top of your watchlist this morning.

But keep in mind, there’s less than 2.8M shares available to the public.

Pull up Moleculin Biotech, Inc. (Nasdaq: MBRX) and start your research.

I’ll check back in with you shortly.

Alex Ramsay

Co-Founder / Managing Editor

Krypton Street Newsletter

KryptonStreet (KryptonStreet . com) is owned by Media 1717 LLC, a limited liability company. Disclosure: I am not a lice.nsed finan.cial adviser. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. KryptonStreet full disclosure is to be read and fully understood before using KryptonStreet website, or joining KryptonStreet’s email or text list. By viewing KryptonStreet website and/or reading KryptonStreet email or text newsletter you are agreeing to KryptonStreet full disclosure which can be read at kryptonstreet.com/disclaimer/

Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 09/22/2024 and ending on 09/23/2024 to publicly disseminate information about (MBRX:US) via digital communications. We have been paid seven thousand five hundred USD. We own zero shares of (MBRX:US). Please see important disclosure information here: https://kryptonstreet.com/mbrx-disclosure-976/